ADMINISTRATION ABSTRACT The Knight Cancer Institute is a matrix organization within OHSU. The Cancer Center Support Grant (CCSG) has been effectively managed by the administrative office under the leadership of the OHSU Knight Cancer Institute Director, Brian Druker, M.D. The past several years have brought tremendous positive change to the cancer institute, including the appointment of world-renowned scientists to serve as Knight senior leaders, recruitment of 32 new cancer researchers, reorganization of research programs, development of an expanded vision for early cancer detection, and successful completion of a $1 billion philanthropic fundraising challenge campaign. The Knight administration plays a critical role in providing resources and expertise to support the strategic initiatives and ongoing operations of the Knight Cancer Institute. The Knight administrative team is led by Kristin Bialobok, Associate Director Administration, who oversees all central operations. Working to prevent duplication, and ensure integration and coordination with the larger OHSU structure, the Knight administrative office acts as a liaison to OHSU central service groups, divisions, and departments across campus. Key activities overseen by the Knight center administrative office include 1) fiscal and grants management; 2) shared resource oversight and support; 3) CCSG membership processes and activities; 4) space management; 3) planning and evaluation activities; 4) strategic communications; 5) business development and commercialization support; 6) information technology support and development; 7) general administration, human resources, and events coordination; 8) communication outreach and engagement; 9) pilot project administration, 10) faculty recruitment management; and 11) organizational development. In the current funding cycle, the Knight administrative team made multiple substantial contributions. Examples of these contributions include: 1) development of a scientific research advocate group; 2) creation and launching of a Community Partnership Initiative; 3) facilitation of design and construction preparation activities for a new Knight cancer research building and a new clinical building; 4) development of new Knight membership and publication tracking system (Galen); 5) implementation of a new Competitive Application Portal for management of internal funding opportunities and external limited submission applications; and 6) implementation of iLabs to streamline management of shared resources. The Knight senior leadership team is composed of Director, Brian Druker, MD; Deputy Director, Tomasz Beer, MD; and Associate Directors, Raymond Bergan, MD, Sara A. Courtneidge, PhD, Lisa M. Coussens, PhD, Joe Gray, PhD, Mary Stenzel-Poore, PhD, and Kristin Bialobok, MSN. Together these leaders are responsible for establishing the institute's goals, guiding its strategic initiatives, and ensuring that basic, translational, and population science initiatives are in alignment.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA069533-20
Application #
9640122
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2018-07-01
Budget End
2019-06-30
Support Year
20
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Oregon Health and Science University
Department
Type
DUNS #
096997515
City
Portland
State
OR
Country
United States
Zip Code
97239
Risom, Tyler; Langer, Ellen M; Chapman, Margaret P et al. (2018) Differentiation-state plasticity is a targetable resistance mechanism in basal-like breast cancer. Nat Commun 9:3815
Minnier, Jessica; Pennock, Nathan D; Guo, Qiuchen et al. (2018) RNA-Seq and Expression Arrays: Selection Guidelines for Genome-Wide Expression Profiling. Methods Mol Biol 1783:7-33
Su, Yulong; Pelz, Carl; Huang, Tao et al. (2018) Post-translational modification localizes MYC to the nuclear pore basket to regulate a subset of target genes involved in cellular responses to environmental signals. Genes Dev 32:1398-1419
Gast, Charles E; Silk, Alain D; Zarour, Luai et al. (2018) Cell fusion potentiates tumor heterogeneity and reveals circulating hybrid cells that correlate with stage and survival. Sci Adv 4:eaat7828
Krey, Jocelyn F; Scheffer, Deborah I; Choi, Dongseok et al. (2018) Mass spectrometry quantitation of proteins from small pools of developing auditory and vestibular cells. Sci Data 5:180128
Rozanov, Dmitri V; Rozanov, Nikita D; Chiotti, Kami E et al. (2018) MHC class I loaded ligands from breast cancer cell lines: A potential HLA-I-typed antigen collection. J Proteomics 176:13-23
Winters-Stone, Kerri M; Wood, Lisa J; Stoyles, Sydnee et al. (2018) The Effects of Resistance Exercise on Biomarkers of Breast Cancer Prognosis: A Pooled Analysis of Three Randomized Trials. Cancer Epidemiol Biomarkers Prev 27:146-153
Pennock, Nathan D; Martinson, Holly A; Guo, Qiuchen et al. (2018) Ibuprofen supports macrophage differentiation, T cell recruitment, and tumor suppression in a model of postpartum breast cancer. J Immunother Cancer 6:98
Xu, Li; Gordon, Ryan; Farmer, Rebecca et al. (2018) Precision therapeutic targeting of human cancer cell motility. Nat Commun 9:2454
Chen, Emerson Y; Blanke, Charles D; Haller, Daniel G et al. (2018) A Phase II Study of Celecoxib With Irinotecan, 5-Fluorouracil, and Leucovorin in Patients With Previously Untreated Advanced or Metastatic Colorectal Cancer. Am J Clin Oncol 41:1193-1198

Showing the most recent 10 out of 277 publications